Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum
Primary Purpose
Obesity, Wound Infection, Pregnancy
Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Kerlix-AMD
placebo--normal gauze
Sponsored by
About this trial
This is an interventional health services research trial for Obesity
Eligibility Criteria
Inclusion Criteria:
- pregnant women at LHSC with BMI >40
Exclusion Criteria:
- pregnant women who cannot understand English, who have a fetal demise or who have a pre-existent infected skin infection at the site of c-section
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Arm Label
Elective LSCS--Kerlix AMD
Elective LSCS--Placebo
Labouring LSCS--Kerlix AMD
Labouring LSCS--Placebo
Arm Description
Kerlix-AMD applied to wound site pre-operatively (3 days) and post-operatively for 2 weeks
Normal gauze applied to wound site pre-operatively for 3 days and post-operatively for 2 weeks
Kerlix-AMD applied to wound post-operatively for 2 weeks
Normal gauze applied to wound post-operatively for 2 weeks
Outcomes
Primary Outcome Measures
surgical site infection
All patients will have their wounds assessed by 6 weeks post partum to evaluate for the presence (or absence) of surgical site infection, using the Centers for Disease Control and Prevention (CDC) Nosocomial Infections Surveillance (NNIS) system criteria.
Secondary Outcome Measures
patient satisfaction
patients will be surveyed on adherence and acceptability of application of gauze post c-section
Full Information
NCT ID
NCT02882360
First Posted
May 12, 2016
Last Updated
August 24, 2016
Sponsor
Lawson Health Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT02882360
Brief Title
Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum
Official Title
The Use of Antimicrobial Gauze in Pregnant Women Undergoing C-section With BMI >40 to Decrease Wound Complications by 6 Weeks postpartum--a Small Feasibility Study
Study Type
Interventional
2. Study Status
Record Verification Date
August 2016
Overall Recruitment Status
Unknown status
Study Start Date
October 2016 (undefined)
Primary Completion Date
January 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Lawson Health Research Institute
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Pregnant women with BMI>40 will be approached for participation in a study to reduce the rate of post-operative wound infection from C-section. Women will be randomized to a commonly used wound product (Kerlix-AMD) which consists of a PHMB-impregnated gauze versus normal gauze, and rates of post-operative surgical site infection will be assessed. Women with a planned procedure will also be randomized to applying Kerlix versus gauze for 3 days pre-operatively to determine if this improves outcomes as well.
Detailed Description
This study be a randomized double-blinded feasibility study to improve the rates of wound complications post-C/S in women with a BMI >40. It will be conducted out of a single tertiary care centre in London, Ontario. The women will be randomized to one of two treatment groups, either Kerlix AMD gauze or Kerlix plain gauze (Kendall, Covidien AG, Mansfield MA). This randomization will be performed by validated computer based randomization software (www.sealedenvelope.com). The patients, staff and physicians will be blinded to the assigned groups. After consenting to the study, at the time of their C/S, participants will be assigned a sealed envelope which will contain their assigned group. All patients with a BMI >40 who qualify for the study that are seen in the outpatient clinics at our centre will be approached about their participation in the study. Patients that meet the study criteria who are seen for the first time after being admitted to the labor and delivery ward will be consented for the study, and if they do not require a C/S, then this consent will be disregarded. Participants who have a planned C/S will also be randomized to receive treatment with either AMD or plain gauze for three days prior to their C/S. This requires placement of a piece of gauze, randomly assigned, under the pannus in the area of the anticipated incision. This gauze is to be changed daily for three days prior to the booked C/S. These patients will continue to receive the same gauze they were assigned to post-operatively. As part of routine care peri-operatively, all patients receive 3g of Ancef 15-60 min prior to skin incision (Ayres-de-Campos), and their skin is prepped with 2% chlorohexidine (Lee I) (2%, Laboratoire Atlas Inc, Montreal, QC) . The subcutaneous layer will be closed at the end of the case using absorbable sutures (Chelmow). The skin will be closed with a running absorbable suture in the subcuticular layer (Clay). At the end of the C/S, all patients will have their respective gauze placed over their incision, with a Tegaderm (3M Healthcare, St. Paul, MN) or pressure dressing placed on top. This outer occlusive dressing will be removed poat-operative day )POD) 1, unless it becomes saturated before then. Their gauze will be replaced daily, or more frequently if it becomes saturated. The incisions will be inspected daily by a physician while they are in hospital. The Centers for Disease Control and Prevention (CDC) Nosocomial Infections Surveillance (NNIS) system criteria will be used to diagnose wound infections. They will be discharged home with enough gauze for daily dressing changes for two weeks, as well as an information sheet outlining signs and symptoms to be aware of, or reasons to return to hospital. Their incision will be inspected by a physician at one, two and six weeks post-operatively. If at any point over the duration of the study they develop signs or symptoms of infection or any other complications, they will be investigated and treated accordingly. This may involve taking a picture of the wound to track whether or not cellulitis or infection is spreading or tracking; this will always be with your explicit consent and to track wound progression. At six weeks they will also complete a qualitative survey investigating their subjective experience with the gauze and the protocol. A cost analysis will also be performed. All data will be collected using data collection sheets. The newest version of Statistical Package for Social Sciences (SPSS) Statistical analysis software will be used to conduct data analysis, using formulas such as student t-test for continuous data and chi-squared for nominal data.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Wound Infection, Pregnancy
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Elective LSCS--Kerlix AMD
Arm Type
Experimental
Arm Description
Kerlix-AMD applied to wound site pre-operatively (3 days) and post-operatively for 2 weeks
Arm Title
Elective LSCS--Placebo
Arm Type
Placebo Comparator
Arm Description
Normal gauze applied to wound site pre-operatively for 3 days and post-operatively for 2 weeks
Arm Title
Labouring LSCS--Kerlix AMD
Arm Type
Experimental
Arm Description
Kerlix-AMD applied to wound post-operatively for 2 weeks
Arm Title
Labouring LSCS--Placebo
Arm Type
Placebo Comparator
Arm Description
Normal gauze applied to wound post-operatively for 2 weeks
Intervention Type
Device
Intervention Name(s)
Kerlix-AMD
Intervention Description
Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
Intervention Type
Other
Intervention Name(s)
placebo--normal gauze
Intervention Description
Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
Primary Outcome Measure Information:
Title
surgical site infection
Description
All patients will have their wounds assessed by 6 weeks post partum to evaluate for the presence (or absence) of surgical site infection, using the Centers for Disease Control and Prevention (CDC) Nosocomial Infections Surveillance (NNIS) system criteria.
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
patient satisfaction
Description
patients will be surveyed on adherence and acceptability of application of gauze post c-section
Time Frame
6 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
pregnant women at LHSC with BMI >40
Exclusion Criteria:
pregnant women who cannot understand English, who have a fetal demise or who have a pre-existent infected skin infection at the site of c-section
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Debbie Penava, MD
Phone
5196466401
Email
Debbie.Penava@lhsc.on.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer Ryder, HBSc, MHS
Phone
519-685-8781
Email
Jennifer.Ryder@lhsc.on.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Debbie Penava, MD
Organizational Affiliation
Lawson Health Research Institute
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum
We'll reach out to this number within 24 hrs